<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Three marrow transplant recipients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> (two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, one <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) experienced prolonged <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> after allogeneic BMT following conditioning with non-TBI regimens containing high-dose <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (Bu/CY), despite the use of G-CSF </plain></SENT>
<SENT sid="1" pm="."><plain>Early recovery of host-derived hematopoiesis ensued </plain></SENT>
<SENT sid="2" pm="."><plain>Although neutrophil counts in these patients exceeded 500 x 10(6)/l by day 30 after transplant, these cells were of host origin </plain></SENT>
<SENT sid="3" pm="."><plain>This early recovery of host-derived hematopoiesis has been observed rarely among patients conditioned with TBI-based regimens </plain></SENT>
<SENT sid="4" pm="."><plain>When patients conditioned with Bu/CY show delayed hematologic recovery, mixed chimerism should be considered even in the presence of <z:mpath ids='MPATH_458'>normal</z:mpath> neutrophil recovery </plain></SENT>
</text></document>